Commonwealth Financial Services LLC Increases Holdings in Pfizer Inc. $PFE

Commonwealth Financial Services LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,642 shares of the biopharmaceutical company’s stock after buying an additional 4,128 shares during the quarter. Commonwealth Financial Services LLC’s holdings in Pfizer were worth $937,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. CWM LLC increased its stake in Pfizer by 6.0% during the second quarter. CWM LLC now owns 1,488,909 shares of the biopharmaceutical company’s stock worth $36,091,000 after acquiring an additional 84,187 shares during the last quarter. Sippican Capital Advisors increased its stake in Pfizer by 37.4% during the second quarter. Sippican Capital Advisors now owns 92,912 shares of the biopharmaceutical company’s stock worth $2,252,000 after acquiring an additional 25,285 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Pfizer by 26.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 504,446 shares of the biopharmaceutical company’s stock worth $12,230,000 after acquiring an additional 105,453 shares during the last quarter. Concurrent Investment Advisors LLC increased its stake in Pfizer by 11.5% during the second quarter. Concurrent Investment Advisors LLC now owns 200,775 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 20,663 shares during the last quarter. Finally, Inman Jager Wealth Management LLC increased its stake in Pfizer by 14.7% during the second quarter. Inman Jager Wealth Management LLC now owns 40,084 shares of the biopharmaceutical company’s stock worth $972,000 after acquiring an additional 5,124 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.35.

Pfizer Trading Down 1.7%

PFE opened at $24.81 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.82. The stock has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.81 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business has a fifty day moving average price of $24.86 and a 200 day moving average price of $24.13.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.